F/TAF is approved as a safer, non-inferior PrEP option compared with F/TDF. With generic F/TDF expected in 2020, we examine how much more payers should be willing to pay for the improved safety profile of branded F/TAF.
We assembled safety data for F/TAF and F/TDF in an age-stratified population of 123,610 US MSM without HIV and from studies of people with HIV. Data were used to forecast fractures, ESRD cases, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) over 5y. To determine the maximum price differential for F/TAF (currently $16,600/year, Federal Supply Schedule) over generic F/TDF, we portrayed F/TAF as favorably as possible, ignoring any ASCVD effects and overstating its safety. For example, we assumed for those on F/TDF that: 1) severe loss of bone mineral density resulted in osteoporosis-related fractures and that all fractures occurred at the hip, leading to a one year 30% quality of life (QoL) decrement and a cost of $70,400; 2) background ESRD rates were more than double their reported value and ESRD was immediate and irreversible, resulting in a 47% QoL decrement and costs of $92,100-$95,500 each year; and 3) the generic F/TDF alternative would achieve a modest (50%) price reduction to $8,300/year. We also examined the budget impact of F/TDF vs. F/TAF, comparing PrEP coverage and transmissions.
Compared to F/TDF, F/TAF averted 2,101 fractures and 30 ESRD cases, the ICER exceeded $7 million/QALY gained (Table). At a willingness to pay of $100,000/QALY, the maximum justifiable price for F/TAF was $8,680/year. Even among patients at highest risk of fracture and ESRD (>55y), the ICER for F/TAF exceeded $3 million/QALY and the maximum justifiable price was $9,020/year. Results were robust to alternative time horizons and PrEP-using population sizes; regardless of age and F/TDF costs, the maximum justifiable markup over generic F/TDF was <$750/yr. Using the entire US HIV prevention budget ($900.8M) and base case assumptions of F/TAF and F/TDF costs, 54,270 people could receive F/TAF and 105,210 could receive F/TDF annually; this difference in PrEP coverage would result in an additional 8,610 new HIV infections with F/TAF.
Given its minimal impact on adverse events, F/TAF justifies a markup no greater than $750 over generic F/TDF in the US. At a higher price, it may well do more harm than good.